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Abstract
Background: To study the prevalence of chronic kidney disease (CKD) and its impact on allopurinol dosing and
uric acid control among patients with gout.
Methods: This was a retrospective study using data from a large US health plan. Claims and laboratory data were
analyzed for enrollees from the health plan database from January 2002 through December 2005. Patients with
gout were identified from pharmacy and medical claims data based on the presence of codes for gout medication
or gout diagnosis. Severity of CKD was determined using the estimated glomerular filtration rate (eGFR). Allopurinol
titration was defined as a change in average daily dose from first prescription to last prescription of ≥ 50 mg.
Results: A total of 3,929 patients were identified for inclusion in this study, 39% of whom had CKD (based on
having an eGFR < 90 mL/min/1.73 m
2). Subjects with CKD were older (p < 0.01) and more likely to be women (p
< 0.01), had a greater number of comorbid conditions (p < 0.01), and were more likely to be prescribed allopurinol
(p < 0.01) compared to those with no CKD. The average starting dose of allopurinol was lower among those with
CKD, and it decreased with worsening kidney function. Among the 3,122 gout patients who used allopurinol, only
25.6% without CKD and 22.2% with CKD achieved a serum uric acid concentration of < 6.0 mg/dL (p = 0.0409).
Also, only 15% of allopurinol users had an upward dose titration (by ≥50 mg), but the average increase in dose did
not differ significantly between those with and without CKD.
Conclusions: About two out of every five patients with gout in this population had CKD. Allopurinol doses were
not adjusted in the majority of CKD patients. Serum uric acid control in gout was poor among patients without
CKD and even worse among those with CKD.
Background
Gouty arthritis (gout) is relatively common in the gen-
eral population, with an estimated prevalence of 4%, and
it is associated with approximately 3.9 million ambula-
tory care visits per year [1,2]. Chronic kidney disease
(CKD) is also common, affecting approximately 26 mil-
lion adults in the United States over the age of 20 [3,4].
Specific lifestyles choices can influence the risk of gout,
but lifestyle changes may not be sufficient to manage
disease after the onset of gout [5].
Gout patients typically exhibit increased levels of
serum uric acid. It is recommended that serum uric acid
levels be lowered to a target of < 6 mg/dL to better
manage gout symptoms, and to reduce synovial MSU
crystals and acute gout attacks [6]. Uric acid is excreted
primarily through the kidney, and any impairment of
kidney function can result in hyperuricemia. Even
among individuals with normal renal function, the pre-
sence of hyperuricemia has been correlated with future
incidence of renal impairment and increased healthcare
utilization and costs [7,8]. Treatment of gout in patients
with CKD is complicated because full dosing of allopuri-
nol, the uric acid-reducing medicine, requires adequate
renal function to clear oxypurinol, its active metabolite
[9]. It is recommended that patients with renal impair-
ment should receive reduced doses of allopurinol, as
they may be at increased risk for allopurinol-related
toxicity [9]. However, suboptimal uric acid control has
been associated with worsening renal function [10-12].
Studies suggest that the prevalence of both gout and
CKD are likely to increase over time [3,4]. Although the
vast majority of patients with gout in the United States
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studies of CKD in gout patients have been performed in
other settings such as rheumatology clinics [12-15], dia-
lysis databases [16], and renal transplant centers [17,18].
I nt h ep r e s e n ts t u d y ,ar e t r o s p e c t i v ea n a l y s i sw a sp e r -
formed using a large US health plan database (and asso-
ciated lab data) containing detailed information on gout
diagnosis, urate-lowering therapy usage, and serum uric
acid (sUA) levels. The objectives of this study were to
determine the prevalence of CKD among a general
population of gout patients in a normal practice setting,
and to investigate the impact of CKD on allopurinol
dosing and uric acid control.
Methods
Data source and study design
This was a retrospective analysis of medical and phar-
macy claims data from a large managed health care plan
in the United States affiliated with OptumInsight. Addi-
tional laboratory data for patients was also obtained for
some analyses. During the period of this study (January
1, 2002 through December 31, 2005), the health plan
covered approximately 14 million individuals, mainly in
the United States. The data were used in a de-identified
format that complied with the requirements of the
Health Insurance Portability and Accountability Act
(HIPAA).
Patient identification
This study included commercial health plan members at
least 18 years of age. Ideally, a gout diagnosis would be
based on the demonstration of intracellular urate crys-
tals in an appropriate clinical setting, or on clinical or
survey criteria published by the American College of
Rheumatology [19,20]. However, these approaches are
not feasible in large retrospective studies such as this
one. In this study, patients were considered to have gout
and were selected for the study if they had a minimum
of 2 qualifying claims (as described below) during the
time period from January 2002 through December 2005.
The first qualifying claim must have been a prescription
claim for a gout medication (allopurinol, probenecid,
colchicine, and/or sulfinpyrazone). The second qualify-
ing claim may have been either a prescription claim for
a gout medication or a medical claim with an Interna-
tional Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) diagnosis code of 274.0.
Patients were also required to have at least 1 serum
creatinine laboratory result during the first 12 months
of their follow-up period for study inclusion. Patients
with evidence of dialysis, kidney transplant, and/or can-
cer during the study period were excluded from the ana-
lysis. To qualify patients were also required to be
enrolled in the health plan for ≥ 365 days during a
baseline period and for ≥ 365 days during a follow-up
period.
Measurements of kidney function and uric acid
The Modification of Diet in Renal Disease (MDRD)
study equation was applied to patients’ serum creatinine
levels to estimate the glomerular filtration rate (eGFR)
[21]. The definition and stages of CKD used for the
study are based on staging described by the National
Kidney Foundation Kidney Disease Outcomes Quality
Initiative (NKF KDOQI™, as found at http://www.kid-
ney.org/professionals/kdoqi/guidelines_ckd/toc.htm),
with modifications as described below. All patients with
eGFR ≥90 were defined as having no CKD (information
on kidney damage in the presence of normal eGFR was
unavailable, so NKF Stage 1 disease was rolled into the
“no CKD category”). Patients with NKF Stage 2 disease
(eGFR 60-89), NKF Stage 3 disease (eGFR 30-59), or
NKF Stage 4 disease (eGFR 15-29) were defined as hav-
ing CKD and assigned to the Stage 2 (mild disease) cate-
gory, the Stage 3 (moderate disease) category, or the
Stage 4 (severe disease) category, respectively. Patients
with NKF Stage 5 disease (kidney failure, eGFR < 15)
were rolled into the Stage 4 (severe disease) category,
due to small sample size. As some patients may have
had more than one eGFR value, determination of CKD
stage was based on the last eGFR value in the follow-up
period. Follow-up eGFR was used instead of baseline
eGFR because not all patients had a baseline GFR, and
as renal function deteriorates over time, the follow-up
eGFR was expected to classify patients by their most
severe disease indicator.
Patients’ serum uric acid levels were obtained from
laboratory data. In accordance with available guidelines,
a serum uric acid concentration < 6 mg/dL (< 0.36
mmol/L) was designated as the desirable goal for gout
patients receiving urate reduction therapy [22]. Patients
were stratified by CKD stage, and the proportion of
patients at goal was determined.
Patient demographic and clinical characteristics
Patient demographic variables including age, gender, and
geographic location were identified from the enrollment
data. ICD-9-CM codes from medical claims were used
to calculate scores for the Charlson-Deyo Comorbidity
Index, a validated index of severity of comorbidity [23].
A validated comorbidity classification developed by Elix-
hauser and adopted by the US Agency for Healthcare
Research and Quality (AHRQ) was used to examine
gout-kidney disease relationships across comorbidity
groups [24].
In a subset analysis, the proportion of gout patients
receiving allopurinol prescriptions (medication fill rate)
was evaluated. In addition, the allopurinol average daily
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and at the time of last observation. Patients were con-
sidered to have titrated their allopurinol dose if the
absolute change in average daily dose from first pre-
scription to last prescription was ≥ 50 mg. Additional
analyses were conducted using a threshold of change in
allopurinol dose of ≥100 mg to define therapy titration.
Other medications for gout such as probenecid, colchi-
cine, and sulfinpyrazone were used too infrequently in
the study sample for meaningful analysis.
Data analysis
For univariate and bivariate analyses, Student’s t-test
and Pearson’s chi-squared test, respectively, were used.
For multivariable analyses designed to determine factors
associated with changes in allopurinol dose, a logistic
regression with occurrence of a dose change of ≥50 mg/
day was used as the dependent variable. Independent
variables included severity of CKD, age, gender, region
of plan membership, thiazide use, preexisting comorbid
conditions, and length of allopurinol therapy. All ana-
lyses were conducted using the SAS (version 9.0) soft-
ware program (SAS Institute, Inc., Cary, North
Carolina).
Results
Patient selection and characteristics
A total of 220,763 patients were initially identified from
the health plan database, based on the presence of at
least 1 medical claim for gout or 1 fill for gout medica-
tion between 1/1/02 and 12/31/05 (Figure 1). After
application of age criteria, continuous enrollment cri-
teria, and criteria requiring no cancer during baseline,
41,290 patients remained. Of these 41,290 patients,
19,828 met the study criteria for having gout. The sam-
ple was further reduced to only include patients with
available serum creatinine results during the first 12
months of follow-up. After application of all inclusion
and exclusion criteria, a final sample of 3,929 patients
was selected for the study.
Of the 3,929 patients who met the inclusion criteria,
1,536 (39%) were identified as having CKD. In a sensi-
tivity analysis using the first serum creatinine measure-
ment during the first 12 months (rather than the last
measurement), subject distribution among CKD stages
was similar. More than half (67.2%) of the subjects with
CKD had Stage 2 CKD, 23.2% had Stage 3 CKD, and
9.6% had Stage 4 CKD (Table 1). CKD subjects were
older (p < 0.0001) and more likely to be female (p =
0.0082) than those without CKD (Table 1). CKD
patients had a greater number of comorbid conditions
(p < 0.0001) and a higher Charlson-Deyo Comorbidity
Index score (p < 0.0001) as compared to subjects with-
out CKD. The five most common comorbid conditions
observed in both patients with CKD and those without
CKD were hypertension (67.6% of CKD patients vs.
48.5% of non-CKD patients); dyslipidemia (54.2% vs.
45.1%); non-gout arthropathies (35.4% vs. 34.4%); cardi-
ovascular diseases (32.5% vs. 25.6%); and diabetes melli-
tus (25.8% vs. 16.4%). There was not a statistically
significant difference in the length of follow-up between
patients with CKD and those without CKD.
Serum uric acid levels and allopurinol use
A total of 3,122 gout patients used allopurinol at least
once during the study period (79% of the study popula-
tion). Only 77.5% of patients without CKD were pre-
scribed allopurinol, compared to 80.0% of patients with
Stage 2 CKD, 87.4% of patients with Stage 3 CKD, and
87.8% of patients with Stage 4 CKD. However, the mean
follow-up serum uric acid level among allopurinol users
with CKD was significantly higher than for allopurinol
users without CKD (7.11 mg/dL vs. 6.75 mg/dL; p <
0.0001) (Table 2). Further, 25.6% of allopurinol users
without CKD as compared to only 22.2% of allopurinol
users with CKD reached the serum uric acid goal of <
6.0 mg/dL during the follow-up period (p = 0.0409).
The mean initial dose of allopurinol decreased signifi-
cantly with increasing severity of CKD (Table 3). Patients
with Stage 2 CKD had a mean initial allopurinol dose of
249.0 mg/day, compared to 233.8 mg/day for patients with
Stage 3 CKD and 217.6 mg/day for patients with Stage 4
CKD. The majority of patients who used allopurinol did
not titrate their medication dose during the study period.
Only about 14.6% of patients without CKD and 15.6% of
patients with CKD had a dose titration. Although there
was no significant difference in likelihood of dose titration
between all patients with CKD vs. those without CKD (p =
0.45), patients with Stage 4 CKD were significantly more
likely to have a dose titration compared to patients with-
out CKD (p < 0.0001). Titration of dose upwards was
more common than titration of dose downwards, both
among patients with CKD and those without CKD (Table
3). We compared initial daily dose of allopurinol to the
maintenance doses recommended by Hande et al. [9]
using eGFR as a surrogate for creatinine clearance (Table
4). We found that 95.6% of subjects with an eGFR 100 or
higher had an initial dose that did not exceed the recom-
mended maintenance dose; however, this percentage was
only 33.3% for eGFR 20-99, and 1.2% for eGFR0-19.
Multivariable logistic regression analysis was used to
assess factors associated with titration (Table 5). Adjust-
ing for covariates, patients with severe CKD had a sig-
nificantly higher likelihood of dose titration compared
to allopurinol users without CKD (odds ratio [OR]
2.130, 95% confidence interval [95% CI]: 1.380 - 3.289).
Other factors associated with dose titration were thia-
zide use during follow-up (OR 1.301, 95% CI 1.035 -
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bidity Index score (OR 1.164, 95% CI 1.059 - 1.279).
Increased age was associated with a decreased odds of
dose titration (OR 0.973, 95% CI 0.962 - 0.985). Results
using a threshold for titration of ≥100 mg were similar.
Discussion
The prevalence of CKD in the US general population is
approximately 13% [3]. This retrospective study reveals
av e r yh i g hp r e v a l e n c eo fC K D( a p p r o x i m a t e l y4 0 % )
among gout patients in the US. A previous smaller
study of gout patients in New Zealand found a level of
CKD prevalence similar to what is reported here [25]. In
the present study, gout patients with severe renal disease
were somewhat older and more likely to be female and
to have a greater overall comorbidity burden. As
expected, serum uric acid concentrations were higher
among those with worse renal disease. Although indivi-
duals with CKD were treated more frequently, they
received lower initial doses of allopurinol. Over time,
Age <18 and 
information on gender 
missing 
n=912 
Not continuously 
enrolled for 365 days 
during baseline period 
or for  365 days during 
follow-up period 
n=139,023 
Remaining sample 
n=41,290 
Evidence of cancer 
during baseline 
n=39,538 
Did not meet 
following gout 
criteria: 
•  2 prescription fills 
for gout medications 
OR•  1 medical 
claim with a gout 
diagnosis and 1 
prescription for a gout 
medication 
n=21,462 
Did not have 
1 creatinine test 
during follow-up 
n=13,943 
Did not have a 
creatinine test during 
the first 12 months that 
could be used to assign 
severity of renal 
disease n=1,877 
Final sample size 
n=3,929 
Evidence of dialysis 
or kidney transplant 
n= 79
Starting sample of pts with at least 
1 medical claim for gout or at least 
1 prescription fill for a gout 
medication, from 1/1/02 through 
12/31/05  
n=220,763 
 
Figure 1 Patient selection. A total of 220,763 patients with at least 1 medical claim for gout or 1 fill for gout medication between 1/1/02 and
12/31/05 were initially identified from the health plan database. After application of all inclusion and exclusion criteria, a final sample of 3,929
patients was selected for the study.
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increased regardless of the presence or severity of renal
disease. The magnitude of increase among those with
renal disease was smaller but statistically indistinguish-
able from those with normal renal function. Thus, the
treatment received by those with normal renal function
was not substantially more aggressive than the treatment
received by those with impaired renal function.
Within each cohort, patients who used allopurinol had
lower serum uric acid levels than patients who did not
use allopurinol. However, a significant finding of this
study was the relatively low proportion of patients trea-
ted with allopurinol who achieved a serum uric acid
concentration of < 6 mg/dL (25.6% of patients without
CKD, 23.3% of those with Stage 2 CKD, 20.2% of those
with Stage 3 CKD, and 18.8% of those with Stage 4
CKD). Although goal attainment was low among all
patient cohorts, presence of CKD decreased the likeli-
hood of meeting this benchmark even further. Further, a
low percentage of patients with CKD (only about 16%)
had their allopurinol dosage titrated. These findings
highlight the therapeutic challenge of balancing the risks
and benefits of administering allopurinol to patients
with impaired renal function.
Appropriate dosing of allopurinol when CKD is pre-
sent is an important yet controversial topic. The US
Food and Drug Administration has approved the follow-
ing dosing regimen for gout without concurrent renal
Table 1 Patient characteristics at baseline
Patient characteristics No
CKD
(n)
No
CKD
(%)
Stage 2 CKD
(n)
Stage 2 CKD
(%)
Stage 3
CKD
(n)
Stage 3
CKD
(%)
Stage 4
CKD
(n)
Stage 4
CKD
(%)
p-
value*
All patients 2,393 - 1,032 - 357 - 147 -
Age group (years)
≤44 858 35.85 138 13.37 38 10.64 33 22.45 < .0001
45-64 1,503 62.81 812 78.68 264 73.95 104 70.75
65-74 31 1.3 79 7.66 48 13.45 9 6.12
75+ 1 0.04 3 0.29 7 1.96 1 0.68
Male gender 2,121 88.63 896 86.82 300 84.03 120 81.63 0.0082
mean SD mean SD mean SD mean SD
Number of comorbidities 6.85 4.81 7.51 5.33 9.68 5.83 8.19 5.53 < .0001
Charlson-Deyo Comorbidity Index
score
0.44 0.87 0.55 0.94 1.25 1.43 1.33 1.66 < .0001
Age 47.83 9.02 53.71 8.5 57 8.74 51.52 9.81 < .0001
Length of follow-up (days) 912.68 449.7 927.12 455.37 896.94 428.41 936.73 467.52 0.634
eGFR (last value) 109.57 12.62 76.94 8.29 47.79 8.46 19.09 6.87 < .0001
SD = standard deviation.
Table 2 Serum uric acid lab results
Patient Characteristics
No CKD
(N = 2,393)
Stage 2
CKD
(N = 1,032)
Stage 3
CKD
(N = 357)
Stage 4
CKD
(N = 147) p-value
Number of subjects with a lab result N 1,542 645 220 73
% 64.44 62.5 61.62 49.66 0.0033
Value of last sUA test during follow-up period: all subjects mean 6.86 7.09 7.56 7.72 < .0001
SD 1.9 1.9 2.1 2.11
Achieved goal of < 6 mg/dL based on last test during follow-up: all
subjects
n 526 191 50 16
% 34.11 29.61 22.73 21.92 0.0008
Value of last sUA test during follow-up period: allopurinol users mean 6.75 6.93 7.46 7.56 < .0001
SD 1.91 1.85 2.11 2.05
Achieved goal of < 6 mg/dL based on last test during follow-up:
allopurinol users
n 448 172 49 16
% 25.64 23.31 20.16 18.82 0.1247
SD = standard deviation.
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increase by 100 mg/day at weekly intervals until the
desired therapeutic response is achieved. A maximum
dose of 800 mg/day is permitted. However, in a Japanese
study, patients achieved a therapeutic serum concentra-
tion of oxypurinol (> 4.6 mcg/mL) and a clinical
response rate of > 90% at an allopurinol dose of just
100-200 mg/day [27]. Dosing in this study was based on
levels of serum creatinine, not on eGFR. Others have
raised concerns about the safety of higher doses of allo-
purinol, and using serum creatinine as an index for allo-
purinol dosing has been shown to be less safe than
using eGFR [28]. Adhering to the current guidelines for
dosing allopurinol based on eGFR, on the other hand,
does not necessarily result in desired uric acid control
[9,29,30]. The results of the managed care analysis per-
formed here reflect this therapeutic challenge.
Our findings do not indicate that initial daily dose of
allopurinol is prescribed in a manner that correlates
with published guidelines sensitive to renal function.
The original guidelines for allopurinol dosing were
based on an extensive review of severe adverse reac-
tions to allopurinol and a small de novo study of 40
patients [9]. That study calculated that renal clearance
of oxypurinol was directly proportional to the creati-
nine clearance, which was calculated using the Cock-
roft-Gault formula. The recommended dosing levels
were based on achieving a target serum oxypurinol
level of 30-100 mmol/L and not on avoiding any toxi-
city threshold. In another study based on data from a
rheumatology practice, there were modest correlations
between allopurinol doses and plasma oxypurinol con-
centrations, and between creatinine clearance and
plasma oxypurinol [30]. However, there was no corre-
lation between plasma oxypurinol and plasma uric
acid, and only 50% of patients within the therapeutic
r a n g eo fp l a s m ao x y p u r i n o lh a dap l a s m au r i ca c i d
level < 0.42 mmol/L [30]. Collectively, these findings
suggest that there is considerable heterogeneity in drug
handling, and future studies need to test the underly-
ing assumption that oxypurinol is the sole active meta-
bolite responsible for therapeutic efficacy and toxicity.
Concerns regarding adverse events in particular may
influence the aggressiveness of current treatment regi-
mens. Cutaneous adverse reactions to allopurinol
occur in approximately 7.7 per 1000 recipients [31],
and the incidence of allopurinol hypersensitivity syn-
drome is about 2-3 times higher among renally
impaired patients compared to non-renally impaired
patients [32]. However, the relationship between
adverse events and allopurinol dosing is still not fully
understood. Previous studies have shown that patients
receiving doses of allopurinol above the recommended
dose (as based on the creatinine clearance rate) did
not exhibit increased toxicity [33,34]. Other studies
have indicated that specific genetic markers may
Table 3 Allopurinol use
Patient characteristics No CKD
(N = 2,393)
Stage 2
CKD
(N = 1,032)
Stage 3
CKD
(N = 357)
Stage 4
CKD
(N = 147)
p-value
Used allopurinol during follow-up period, including index date N 1,855 826 312 129
% 77.52 80.04 87.39 87.76 < .0001
Initial daily dose (mg) N 1,855 826 312 129
Mean 248.17 249.02 233.78 217.63 0.0023
Std 107.41 107.45 103.73 104.55
Median 300 300 300 200
Last daily dose (mg) N 1,552 699 260 109
Mean 268.93 261.63 248.08 241.54 0.0021
Std 106.46 102.43 94.11 127.4
Median 300 300 300 300
Difference between last dose and initial dose among subjects who
titrated (mg)
N 269 108 53 36
Mean 106.02 102.73 66.26 86.33 0.5366
std 192.07 188.55 167.93 187.99
Subjects who titrated n 270 108 53 36
% 14.56 13.08 16.99 27.91 0.00014
Increased between first and last dose n 213 87 37 27
% 78.89 80.56 69.81 75 0.4253
Decreased between first and last dose n 57 21 16 9
% 21.11 19.44 30.19 25 0.4253
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Hande et al. Creatinine
Clearance
Hande et al. Criteria Maintenance Dose of
Allopurinol
Study Sample
eGFR
Study Sample Initial Daily Dose of
Allopurinol
mg
0 100 mg every 3 days 0-9 n 22
mean 240.91
dose ≤ Hande maintenance dose (%) 0
10 100 mg every 2 days 10-19 n 60
mean 233.14
dose ≤ Hande maintenance dose (%) 1.67
20 100 mg daily 20-39 n 114
mean 208.95
dose ≤ Hande maintenance dose (%) 34.21
40 150 mg daily 40-59 n 245
mean 236.35
dose ≤ Hande maintenance dose (%) 29.8
60 200 mg daily 60-79 n 471
mean 244.46
dose ≤ Hande maintenance dose (%) 35.46
80 250 mg daily 80-99 n 892
mean 249.58
dose ≤ Hande maintenance dose (%) 32.96
100 300 mg daily 100-119 n 909
mean 247.34
dose ≤ Hande maintenance dose (%) 95.93
120 350 mg daily 120-139 n 389
mean 253.09
dose ≤ Hande maintenance dose (%) 94.86
140 400 mg daily 140+ n 20
mean 250
dose ≤ Hande maintenance dose (%) 95
Table 5 Multivariate models predicting an average allopurinol dose change ≥50 mg/day
Odds Ratio 95% Confidence Interval Lower limit 95% Confidence Interval Upper limit p-value
Degree of renal impairment
Stage 2 CKD* 0.939 0.729 -1.208 0.623
Stage 3 CKD* 1.218 0.857 -1.732 0.2723
Stage 4 CKD* 2.13 1.38 -3.289 0.0006
Age 0.973 0.962 -0.985 < .0001
Male gender 0.948 0.686 -1.309 0.7455
Geographic region**
West 1.303 0.83 -2.045 0.2507
South 1.314 1.019 -1.693 0.0353
Northeast 1.641 1.141 -2.362 0.0076
Thiazide use during follow-up 1.301 1.035 -1.635 0.0244
Charlson-Deyo Comorbidity Index score 1.164 1.059 -1.279 0.0016
Months of allopurinol use 1.022 1.015 -1.028 < .0001
*The reference group is patients with no CKD.
** The reference group is the Midwest
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adverse reactions following allopurinol treatment [35].
A few caveats must be considered when interpreting
the results of the present study: (1) The approach used
to identify gout patients from claims data is subject to
misclassification errors. This problem was addressed by
performing sensitivity analyses that specified different
combinations of coding, medications, and laboratory cri-
teria as alternate selection criteria. The resulting patient
populations varied in terms of size and other character-
istics, but the fundamental findings in this analysis held.
(2) Because of the requirement of availability of a serum
creatinine test, the current study population may have
been less renally healthy than other populations of gout
patients. This factor could reduce the generalizability of
the findings. (3) The authors studied patients with gout
seeking medical care, thereby potentially selecting those
with more severe or frequent flare-ups of gout; this, in
turn, may have overestimated the prevalence of CKD
among gout patients. (4) The multivariate model exam-
ining allopurinol dose change did not distinguish
between dose increases or decreases. This would be a
valuable direction for future research. (5) A limitation of
claims analysis is that we are only able to measure pre-
scribed doses, which may differ from the dose that a
patient actually took.
Conclusion
In this study a high prevalence of CKD was observed
among gout patients. Serum uric acid goal attainment
was low among patients treated with allopurinol, and
poorest among those with CKD. The findings suggest
that poor outcomes among gout patients with CKD are
partly due to clinicians’ reluctance to prescribe higher
doses of allopurinol to patients with impaired renal
function. The benefits and risks of allopurinol treatment
must be weighed carefully in patients with CKD, and
alternate treatment approaches are needed to improve
the prognosis of these patients. Future research should
address at least three additional issues: (1) the role of
non-oxypurinol metabolites of allopurinol in efficacy
and toxicity, (2) more sophisticated pharmacogenomics-
based studies of allopurinol dosing in the presence of
CKD, and (3) development of urate-lowering drugs that
are not renally cleared. Additionally, our results suggest
a need to raise awareness among physicians regarding
the importance of titrating therapy to reach uric acid
goals.
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